NASDAQ:CDNACareDx Stock Price, Forecast & News

$31.60

-0.26 (-0.82 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$31.27

Now: $31.60▼

$32.79

50-Day Range

$20.56

MA: $26.40▼

$31.86

52-Week Range

$13.04

Now: $31.60▼

$41.27

Volume418,100 shs

Average Volume758,444 shs

Market Capitalization$1.38 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.92

CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

3.6 Analyst's Opinion

Consensus Rating
CareDx has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.40, CareDx has a potential upside of 56.3% from its current price of $31.60.
Amount of Analyst Coverage
CareDx has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
CareDx has received 364 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CareDx has received 340 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CareDx has received 51.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote “Outperform” if you believe CDNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CareDx does not currently pay a dividend.
Dividend Growth
CareDx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,533,444.00 in company stock.
Percentage Held by Insiders
Only 3.20% of the stock of CareDx is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CareDx are expected to grow in the coming year, from ($0.54) to $0.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CareDx is -65.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CareDx is -65.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CareDx has a P/B Ratio of 13.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.37 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CDNA

Previous Symbol

CUSIPN/A

CIK1217234

Webwww.caredxinc.com

Phone415-287-2300

Debt

Debt-to-Equity Ratio0.17

Current Ratio2.33

Quick Ratio2.09

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$127.07 million

Price / Sales10.89

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.32 per share

Price / Book13.62

Profitability

EPS (Most Recent Fiscal Year)($0.52)

Net Income$-21,970,000.00

Net Margins-14.53%

Return on Equity-20.72%

Return on Assets-13.59%

Miscellaneous

Employees306

Outstanding Shares43,784,000

Market Cap$1.38 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

CareDx (NASDAQ:CDNA) Frequently Asked Questions

How has CareDx's stock been impacted by COVID-19 (Coronavirus)?

CareDx's stock was trading at $18.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDNA stock has increased by 66.8% and is now trading at $31.60. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CareDx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CareDx.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for CareDx.

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) announced its quarterly earnings results on Thursday, April, 30th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The business earned $38.40 million during the quarter, compared to analyst estimates of $38.26 million. CareDx had a negative net margin of 14.53% and a negative return on equity of 20.72%. The company's revenue was up 47.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 EPS. View CareDx's earnings history.

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $38.3-38.3 million, compared to the consensus revenue estimate of $37.76 million.

What price target have analysts set for CDNA?

5 Wall Street analysts have issued 1-year price targets for CareDx's shares. Their forecasts range from $40.00 to $63.00. On average, they anticipate CareDx's share price to reach $49.40 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price. View analysts' price targets for CareDx.

Has CareDx been receiving favorable news coverage?

News headlines about CDNA stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutCareDx.

Who are some of CareDx's key competitors?

Some companies that are related to CareDx include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC) and Miragen Therapeutics (MGEN). View all competitors.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Roku (ROKU), EXACT Sciences (EXAS), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Activision Blizzard (ATVI), Aduro BioTech (ADRO) and Johnson & Johnson (JNJ).

Who are CareDx's key executives?

CareDx's management team includes the following people:

Dr. Peter Maag, Chairman & CEO (Age 53, Pay $1.08M)
Dr. Reginald Seeto, Pres & Chief Bus. Officer (Age 48, Pay $826k)
Mr. Michael Bell, Chief Financial Officer (Age 51, Pay $686.59k)
Ms. Sasha King M.B.A., Chief Marketing Officer (Age 34, Pay $509.2k)

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (11.71%), BlackRock Inc. (7.28%), Invesco Ltd. (6.30%), State Street Corp (5.88%), Waddell & Reed Financial Inc. (4.51%) and Casdin Capital LLC (2.96%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View institutional ownership trends for CareDx.

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Nuveen Asset Management LLC, Rice Hall James & Associates LLC, Balyasny Asset Management LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Bleichroeder LP, and Rafferty Asset Management LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King, and William A Hagstrom. View insider buying and selling activity for CareDx.

Which major investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Ziegler Capital Management LLC, ArrowMark Colorado Holdings LLC, Redwood Investments LLC, and BlackRock Inc.. View insider buying and selling activity for CareDx.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $31.60.

How big of a company is CareDx?

CareDx has a market capitalization of $1.38 billion and generates $127.07 million in revenue each year. The company earns $-21,970,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. CareDx employs 306 workers across the globe.

What is CareDx's official website?

The official website for CareDx is www.caredxinc.com.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-287-2300 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff